<DOC>
	<DOCNO>NCT02666001</DOCNO>
	<brief_summary>The study conduct assess effect multiple dose BMS-663068 exposure methadone subject stable dose methadone , exposure buprenorphine norbuprenorphine subject stable dose buprenorphine norbuprenorphine .</brief_summary>
	<brief_title>A Study Assess Drug-drug Interaction BMS 663068 With Methadone Also With Buprenorphine/Naloxone</brief_title>
	<detailed_description />
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Naloxone</mesh_term>
	<mesh_term>Buprenorphine</mesh_term>
	<mesh_term>Buprenorphine , Naloxone Drug Combination</mesh_term>
	<mesh_term>Methadone</mesh_term>
	<criteria>1 . Signed Informed Consent 2 . Target population : Subjects methadone maintenance therapy ( inclusion Part 1 ) buprenorphine norbuprenorphine maintenance therapy ( inclusion Part 2 ) , reliably participate oral methadone buprenorphine norbuprenorphine program stable dose least 30 day prior study screen 3 . Male Female Subjects body mass index 18 34 kg/m2 , inclusive 4 . Women child bear potential ( WOCBP ) negative serum urine pregnancy test must breastfeed 5 . Men WOCBP must agree follow instruction contraception 1 . History chronic acute illness , gastrointestinal disease , smoke alcohol abuse 2 . Any Gastrointestinal ( GI ) surgery within 4 week study drug administration could affect absorption 3 . Evidence organ dysfunction clinically significant deviation normal physical examination , vital sign , ECG clinical laboratory determination beyond consistent target population . 4 . History allergy drug , BMS663068 , HIV attachment inhibitor , related compound</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>